STAT3 and breast carcinoma: Thus, in the present study, we aimed to investigate, for the first time, the anti-proliferative activity and the effect on EMT process of azilsartan, which is an Ang II receptor blocker (ARB) [30], against breast cancer cell lines MCF-7 and MDA-MB-231 at the molecular level through examining the NF-kB/IL-6/JAK2/STAT3, TWIST/SNAIL/SLUG and apoptosis signaling pathways.